Today the TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC). HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication. …
ŠTO ISKLJUČITI IZ OVOG ČLANKA:
- Odobrenje Uprave za hranu i lijekove (FDA) za HYFTOR™, koji je prvi lokalni tretman za angiofibrome na licu koji je odobrila FDA kod odraslih i djece od šest godina ili starije koji imaju kompleks tuberozne skleroze (TSC).
- HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication.
- eTurboNews članci su samo za pretplatnike.